NEULANDLABNeuland Laboratories Ltd.

₹16689+2.29%

Market Cap

₹20,928.63 Cr

Stock P/E

118.82

ROCE

23.45%

ROE

18.54%

Book Value

₹1198.60

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Unit 3 capacity validations are on schedule, with expected order fulfillment in FY26.
•
We are excited by the range of customers expressing interest in our services and placing first-time orders.

NEGATIVES

•
Quarter's performance was below expectations for the quarter.
•
Free cash flow turned negative for the quarter.

Peers Summary

Sector Leader

Neuland Laboratories Ltd. stands out in the Pharmaceuticals & Drugs sector with robust growth metrics, high profitability, and a strong balance sheet, positioning it as a leader among peers. It shows a remarkable revenue growth and EPS, along with low debt levels, making it an attractive investment compared to its peers, which exhibit mixed performance.

Key Points

• Neuland Laboratories Ltd. leads in revenue growth and EPS metrics.
• Strong profitability indicated by high ROE and low debt levels.
• Several peers are overvalued with high PE ratios compared to earnings growth.

Top Performers

Neuland Laboratories Ltd.

Highest revenue growth (YoY at 30.84%) and EPS growth (202.736), showcasing superior performance.

Cipla Ltd.

Low PE ratio (23.73) with respectable growth and profitability, making it an attractive investment.

Dr. Reddy's Laboratories Ltd.

Strong profitability metrics with a low PE ratio (15.50) and good revenue growth.

Explore

Watchlists

Command Palette